Lung Cancer (NSCLC)
Conditions
Brief summary
The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns. It is difficult to simultaneously explore multiple treatment modalities through previous clinical studies. Observational studies through real-world research can efficiently convert clinical practice data into clinical treatment evidence. This study aims to observe the treatment patterns and clinical outcomes of advanced NSCLC patients who received first-line immunotherapy checkpoint inhibitor treatment after progression, in order to provide guidance for the second-line treatment options for patients with first-line immunotherapy progress.
Interventions
OTHERObservation
The patients' second-line treatment received and the follow-up observations were retrospectively collected.
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced or metastatic NSCLC that is not curable and confirmed by histological or cytological examination based on the 8th edition of AJCC staging. * Previously received advanced first-line treatment based on immune checkpoint inhibitor drugs. * Has a medical record of disease progression during the first-line treatment. * Complete clinical and pathological data, such as age, gender, smoking history, primary tumor location, differentiation, metastatic site, and imaging and serological review as required.
Exclusion criteria
* First-line treatment with immune checkpoint inhibitor drugs was ≤ 2 cycles. * Excluding patients with incomplete key baseline and treatment information. * Have other potential factors that may affect the study results or result in the premature discontinuation, as determined by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months | The overall survival time of the patients enrolled. |
| Progression Free Survival | Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months | The time of disease progression free survival. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | From 2nd line treatment initiation, assessed up to 24 months | Overall response rate |
| Disease control rate | From 2nd line treatment initiation, assessed up to 24 months | Disease control rate |
| Immune-related adverse events | From 2nd line treatment initiation and before 3rd line treatment, assessed up to 24 months | Immune-related adverse events |
Countries
China
Contacts
CONTACTJianchun Duan, M.D.
PRINCIPAL_INVESTIGATORJianchun Duan, M.D.
Cancer Hospirtal Chinese Academy of Medical Sciences
Outcome results
None listed